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Abstract: The development of an osteogenic bone graft sub-
stitute has important practical and cost implications in many
branches of medicine where bone regeneration is required.
Previous in vitro and small animal (murine) in vivo studies
highlighted a porous hydroxyapatite/poly (DL-lactic acid) com-
posite scaffold in combination with skeletal stem cells (SSCs)
as a potential bone graft substitute candidate. The aim of the
current study was to scale up the bone cell-scaffold construct
to large animals and examine the potential for repair of a
critical-sized defect via an ovine model. SSC seeded scaffolds
(and unseeded scaffold controls) were implanted bilaterally
into ovine femoral condyle critical defects for 3 months. A
parallel in vitro analysis of ovine SSC seeded scaffolds was
also performed. Post mortem mechanical indentation testing
showed the bone strengths of the defect sites were 20% (con-
trols) and 11% (SSC seeded scaffolds) those of normal can-
cellous bone (p<0.01). MicroCT analysis demonstrated new
bone formation within all defects with a mean increase of
13.4% in the control scaffolds over the SSC seeded scaffolds
(p5 0.14). Histological examination confirmed these findings,
with enhanced quality new bone within the control defects.
This study highlights important issues and steps to overcome
in scale-up and translation of tissue engineered products.
The scaffold demonstrated encouraging results as an osteo-
conductive matrix; however, further work is required with cel-
lular protocols before any human trials. VC 2014 Wiley
Periodicals, Inc. J Biomed Mater Res Part A: 00A:000–000, 2014.
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INTRODUCTION
The last decade has seen a number of important develop-
ments in the tissue engineering ﬁeld with advances in scaf-
fold development, cell isolation, and demonstration of
skeletal tissue repair in animal models. However, to date,
relatively few scaffolds have made the transition from labo-
ratory into clinical practice. Hollister et al. state that despite
25 years of research, funding totalling hundreds of millions
of dollars, over 12,000 papers on bone tissue engineering
and over 2,000 papers on bone tissue engineering scaffolds
alone in the past 10 years, “the translation of these thera-
pies to clinical use remains, bluntly, a failure.”1 This theoret-
ical barrier to progress has been termed the “valley of
death,”2 and is present for a number of reasons, the most
pertinent including: (1) The dramatic increase in funding
required to scale-up from relatively inexpensive small ani-
mal studies to large animal studies, (2) the importance of
large animal studies when considering bone regenerative
strategies, which introduce a multitude of other confounding
factors when scaled-up, (3) the additional substantial fund-
ing required for successful large animal trials during the
transition from product/technology development to regula-
tory approval and commercialization.
Despite the difﬁculties surrounding clinical translation, a
number of strategies have been successfully brought to
market. Recombinant human bone morphogenic protein-2
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(rhBMP-2) is the most commercially successful tissue engi-
neered product in orthopaedics, accounting for 25% of all
spinal fusion procedures.3 In addition, autologous cartilage
implantation (ACI) is now more widely employed, especially
in the treatment of cartilage defects in the knee and has
also been trialled in other joints such as the ankle.4,5 The
use of SSCs has also been shown to be of beneﬁt in a cohort
of patients in the treatment of fracture nonunions, as well
as being a useful adjunct to allograft in patients with femo-
ral head avascular necrosis undergoing core decompression
procedures.6–8 In addition, SSCs have been combined with
carrier matrices in the treatment of cartilage defects.
Haleem et al. translated this into a small clinical series of
ﬁve patients will full thickness cartilage defects of the femo-
ral condyle.9 All patients’ symptom scores improved signiﬁ-
cantly over the follow-up period of 12 months. However,
despite these encouraging case series, the combination of
SSCs with carrier modalities has yet to reach widespread
clinical application.
Previous in vitro and small animal in vivo studies high-
lighted a composite polymer hydroxyapatite scaffold in com-
bination with SSCs for potential use as a tissue engineered
bone graft substitute. Scaffold characterization via microCT
and scanning electron microscopy (mean porosity
63.465.4%, pore size 1926 51 lm), cellular viability stud-
ies and shear testing found high molecular weight porous
poly (DL-lactic acid) hydroxyapatite (PDLLA110% HA) com-
posite to display both the mechanical, osteogenic capabil-
ities and tissue compatibility required for clinical use.10–12
The use of large animal models is essential when investigat-
ing bone regenerative strategies, circumventing issues of
translation, scale, nutrient requirements, and lack of rele-
vance of skeletal form and forces present in small animal
models.13,14 The current study set out to investigate the
osseointegration and bone regenerative capacity of the scaf-
fold both with and without the addition of SSCs in a scaled-
up ovine critical sized femoral condyle defect model.
MATERIALS AND METHODS
A timeline depicting the stages of the study is given in
Figure 1.
Sheep selection
Six healthy and skeletally mature (>2 years old) welsh
mule ewes weighing between 60 and 90 kg were obtained,
vetted, and acclimatized in a barn for 4 weeks before use
following approval under the Home Ofﬁce Animals (Scien-
tiﬁc Procedures) Act 1986 (project licence 30/2880).
General anaesthesia
All sheep underwent general anaesthesia before any inter-
ventional procedure, which followed a routine protocol. Pre-
medication consisted of 0.1 mg/kg intramuscular xylazine
injection (Rompun, Bayer PLC, Bury St Edmunds, UK) and
the prophylactic antibiotic 5 mg sodium cefalexin (Ceporex,
Schering-Plough, Welwyn Garden City, UK).
Anaesthesia was induced using 2.5 mg intravenous (IV)
Midazolam (Hypnovel, Roche, Welwyn Garden City, UK) and
2 mg/kg IV ketamine hydrochloride (Ketaset, Fort Dodge
Animal Health Limited, Southampton, UK). The sheep were
FIGURE 1. Timeline depicting the stages of the study. A: Aspiration of iliac crest, B: SSCs grown to confluence in vitro, C: scaffold seeded with
each sheep SSCs in sterile containers. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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then intubated, and general anaesthesia was maintained
using inhaled isoﬂurane, oxygen, and nitrous oxide.
Harvest of skeletal stem cells
Once fully anaesthetized the sheep were placed in the left
lateral position. An area measuring  20 3 20 cm2 directly
over the iliac crest was shaved and thoroughly cleaned
using 10% povidone-iodine (betadine) solution followed by
2% chlorhexidine gluconate solution. A trochar was then
inserted through the cortical bone and 10 mL aspirated.
The aspirate from each sheep was then placed into a sepa-
rate universal container into a cool box for transportation
to the laboratory. The sheep were then allowed to recover
and given analgesia as required. Sheep were housed in a
barn, penned as a group and were fed according to standard
practice, with free access to water from troughs until fur-
ther use.
Expansion of SSC populations
Ten millilitres of basal media (a-MEM with 10% fetal calf
serum with additional 1% penicillin and streptomycin) was
added to the universal tubes containing the aspirates, and
the resultant solutions were passed through 70 lm ﬁlter
cell strainers and into a separate universal containers [All
reagents used for tissue culture were obtained from Sigma-
Aldrich (Poole, Dorset, UK) unless otherwise stated]. The
resultant cell solutions were then centrifuged at 1100 rpm
for 4 min. The supernatants were carefully removed and the
cell pellets re-suspended in 40 mL basal media. These solu-
tions were then placed into four T75 tissue culture ﬂasks
(10 mL per ﬂask), incubated at 37C in 5% CO2 until con-
ﬂuent. Cells were washed in PBS and media changes were
performed every 3–4 days. Fourteen days before the surgi-
cal reimplantation date (at 90% conﬂuence), the cells
were released using 10% trypsin in ethylene diamine tetra-
acetic acid (EDTA). The trypsin was neutralized with the
addition of basal media, and cell pellets obtained via centrif-
ugation (1100 rpm for 4 min). The supernatants were
removed and the cell pellets resuspended in basal media
before determining total cell counts using a haemocytome-
ter. Appropriate dilution with basal media was then
achieved to obtain a concentration of 5 3 105 cells/mL.
Scaffold seeding
The polymer composite (PDLLA110% HA) was produced,
milled, and sterilized as described previously.11,12 Twenty
millilitres of each of the cell solutions was added to 20 mL
of the polymer in a universal container and incubated
(37C, 5% CO2) for 2 h, with gentle agitation every 30 min,
to allow cell adhesion. The solution was then aspirated and
discarded. The seeded scaffold was then placed into individ-
ual wells of a six-well plate, and cultured in osteogenic
media (basal media1100 mM ascorbate-2-phosphate, and
10 nM dexamethasone) for 14 days, with PBS washes every
3–4 days. The control scaffold was treated in exactly the
same manner, but without the addition of the SSCs.
At the end of the incubation period the scaffold was
divided in half for parallel in vivo and in vitro testing.
In vivo ovine study
Operative procedure. Twelve hours before surgery the
sheep were given two analgesic Fentanyl patches (75 mcg/h)
and were randomized to receive scaffold1 SSCs or scaffold
alone to either the right or left side. The sheep underwent
full general anaesthesia as detailed earlier. Under full asep-
tic precautions, 10 cm longitudinal incisions were made
centred over the palpable bony protuberances located on
the medial sides of the medial femoral condyles of each leg,
with careful dissection through subcutaneous tissue, fascia,
muscle, and periosteum to expose the underlying bone. A
customized 8 mm drill bit was used to create a hole with a
consistent depth of 15 mm into the underlying cancellous
bone [Fig. 2 (A,B)]. The SSC seeded scaffolds and control
scaffolds were packed tightly into the holes on their allo-
cated sides such that the holes were ﬁlled [Fig. 2(C,D)]. Two
guide wires were placed superior and inferior to the holes
for radiographic location purposes at a later stage. The peri-
osteum and other layers were closed over the ﬁlled holes
using 2/0 VicrylR suture in order to contain the scaffold
and the skin was closed with interrupted 2/0 EthilonR
sutures and OpSite spray (Smith and Nephew, Hull, UK).
The wounds were dressed with betadine soaked gauze and
wool and crepe bandage. The sheep received a ﬁve day
post-operative antibiotic regime (Ceporex 5 mL OD) with
Fentanyl patches and buprenorphine (0.6 mg) for 72 h after
application of the patches (for analgesia) and regular wound
checks. After surgery, the sheep were housed individually in
pens for 5 days, followed by grouped pens for the remain-
der of the study. No control (empty defect) sheep were uti-
lized in this study as the critical defect nature of the model
had been previously demonstrated.15
Retrieval of specimens. The sheep were euthanized with a
barbiturate overdose (0.7 mg/kg) 13 weeks post implanta-
tion of the specimens. The femoral condyles were harvested
together with the popliteal lymph nodes to assess any
potential inﬂammatory reactions associated with in vivo
polymer use, as indicated by previous studies.16,17
Preparation of condyles. All condyles were prepared and
mechanically tested within 6 h of harvest. The condyles
were placed in a jig and carefully orientated using radio-
graphs and marker wires, such that when cut with a
diamond-edged band saw (EXAKT, Hamburg, Germany), the
specimen-ﬁlled drill holes were transected longitudinally in
the coronal plane at the midpoints. One half of each speci-
men was subsequently taken for immediate mechanical test-
ing and mCT evaluation, and the other half was prepared for
histology.
Mechanical testing
The specimens for mechanical testing were placed onto the
stage of the Z005 static materials testing machine (Zwick/
Roell, Leominster, Herefordshire, UK), and a ﬂat ended metal
indentation rod (diameter 4 mm) was placed in opposition
to the desired test area, with a preload of 10 N applied at a
speed of 5 mm/min. The test areas are shown in Figure 3,
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where areas 1 and 2 correspond to the superﬁcial and deep
regions of the scaffold within the drill hole. Areas A and B
correspond to proximal and distal regions of normal cancel-
lous bone. The indentation rod was advanced at a rate of
10 mm/min, and the force required at each time point
recorded using a load cell.
The data was transferred to a spreadsheet (Excel 2007,
Microsoft, Redmond, WA) and load deformation curves were
generated. The peak value corresponded to the failure of
the test area. The force required at this peak was recorded
for each area under test, and converted into a stress value.
Mean stress values (along with standard deviations) were
calculated for each area of the femora implanted with the
scaffold alone, and those implanted with the scaffold1 SSCs.
Micro computed tomography (lCT) evaluation
After indentation the specimens were frozen until mCT eval-
uation. Samples were scanned using a SkyScan 1176 lCT.
The scans were performed with minimized ring artefacts to
give an 18 lm voxel resolution. Analysis of the recon-
structed images was performed using CTAn (Skyscan, Bel-
gium). The region of interest (corresponding to the volume
within the original drill hole) was extracted manually using
the software, and via comparison with standard phantoms,
FIGURE 3. Mechanical indentation test. (A) The four areas of each specimen used, (B) Specimen under test. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
FIGURE 2. The operative procedure for the femoral condyle defect ovine model. A: Creation of a cavity on the medial femoral condyle using the
customized drill bit, B: the cavity (arrow), C: the scaffold, D: packing the scaffold into the hole. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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new bone was deemed to correspond to all density values
over 0.25. Mean volume of new bone within the region of
interest was calculated for the femora implanted with the
scaffold alone, and those implanted with the scaffold1 SSCs.
Histological examination
Femoral condyle. The other half of the femoral condyle
samples were ﬁxed in buffered formal saline (pH 7.2) for 1
week followed by dehydration through an ascending alcohol
series over a 3-week period. The samples were then inﬁl-
trated with JB4 resin (Ted Pella, Inc., Redding, CA) for 3
weeks, refreshing the solution weekly, and were then
embedded in the same resin. Using a band saw, 5 mm thick
longitudinal slices were taken through the specimens and
from these slices thinner sections measuring between 50
and 80 mm thick were prepared. The sections were attached
to an acrylic slide using UV curable cyano-acrylate glue,
before being ground and polished on an EXAKT grinding
machine. Sections were stained with toluidine blue to stain
the soft tissue followed by paragon to stain the bone, before
being viewed by light microscopy.
Popliteal lymph node. The lymph nodes were ﬁxed in form-
aldehyde, and dehydrated in graded ethanol solutions before
wax embedding on a mounting plate. Seven micrometer sec-
tions were cut, transferred to a water bath and mounted on
slides, before transferring to an oven set to 37C for 4 h.
Samples were subsequently stained using a standard Hae-
matoxylin and Eosin (H1E) stain, and assessed for the
presence of abnormal inﬂammatory cells.
Parallel in vitro study
At the start of the study, the remaining SSC seeded scaffold
was kept for parallel in vitro evaluation. The seeded scaffold
from each sheep was weighed out into multiple, separate
1 gram portions, and each portion was placed into an indi-
vidual well of a 24-well plate and cultured at 37C, 5% CO2
in osteogenic media with PBS washes every 3–4 days.
WST-1 cell viability assay. After 14 days in vitro incubation
(day 1 of ovine experiment), and 8 weeks in vitro incuba-
tion (midpoint of ovine experiment) three portions from
each sheep SSC sample (18 in total) were assessed for cell
viability via a WST-1 assay.
Each portion was submerged in 1 mL 1:10 dilution
WST-1 substrate (Roche, Welwyn Garden City, UK).
Unseeded scaffolds were run in parallel (controls). At 4 h,
samples (3 3 100 ml) were removed from each portion and
analyzed via a Bio-Tek KC4 microplate ﬂuorescent reader
(Bio-Tek) at 410 nm. An increase in absorbance value indi-
cated increased cell number and viability. The mean absorb-
ance value was calculated and the mean control WST-1
absorbance value subtracted.
Alkaline phosphatase speciﬁc activity/DNA assays.
Alkaline phosphatase (ALP) speciﬁc activity was used as a
measure of osteoblastic differentiation on the scaffolds fol-
lowing 2 weeks and 8 weeks of in vitro incubation. Three
portions of SSC seeded scaffold from each sheep were
tested at each time point. The scaffolds were individually
washed in PBS, and ﬁxed in 90% ethanol before air drying.
Samples were then rewashed in PBS, and subsequently sus-
pended in 2 mL of 0.5% Triton X-100. Samples were sub-
jected to three freeze thaw cycles with vigorous agitation
between each freeze. Lysate was measured for ALP activity
using p-nitrophenyl phosphate as substrate in 2-amino-2-
methyl-1-propanol alkaline buffer solution (Sigma, Poole,
UK) and DNA content was measured using Pico Green
(Molecular Probes, Paisley, UK) according to routine manu-
facturer protocol. Ten microlitres of lysate was run in tripli-
cate for each cell seeded sample and control samples on a
plate against two standards, read in triplicate on an ELx
800 and FLx-800 microplate ﬂuorescent reader (Bio-Tek)
and mean and standard deviations calculated. Speciﬁc activ-
ity was expressed as nanomoles of p-nitrophenyl phos-
phate/hr/ng DNA.
Immunostaining. SSC seeded specimens from two sheep
were subjected to immunostaining after 8 weeks in vitro
incubation time. Samples were removed from containers,
washed in PBS and ﬁxed for 24 h by submersion in 4%
paraformaldehyde. This was followed by a 10 minute incu-
bation in 1% bovine serum albumin (BSA) and overnight
incubation in 1 mL of primary antibody (e.g., LF68 (whole
rabbit serum) collagen 1 antibody [1:300 dilution with
PBS/BSA)], followed by three washes in 0.1% PBS Tween.
Appropriate secondary antibody [anti-rabbit antibody (alex-
aﬂuorR 594)] was added for 1 h at room temperature, fol-
lowed again by three 0.1% PBS Tween washes. Finally,
SYTOXR blue (1:100 dilution, 10 minute incubation) was
added as a nuclear counterstain. To ensure speciﬁcity of the
secondary antibody a portion of the samples were treated
without addition of the primary antibody. Primary antibod-
ies were type-1 collagen, osteocalcin and bone sialoprotein.
In order to preserve the polymeric architecture, the sections
were not wax embedded. Confocal microscopy (Leica SP5
Laser Scanning Confocal Microscope and software, Leica
Microsystems, Wetzlar, Germany) allowed 3D topographical
visualization of the surfaces.
Statistics. Mean percentage bone volume in the regions of
interest as measured by mCT in the control group versus the
cell seeded group were compared using a Mann-Whitney U
Test (Prism version 6.03, GraphPad Software, La Jolla, CA).
The biochemical assays at the 2 weeks and 8 weeks time
points were also compared with the same software using a
Mann–Whitney U Test.
RESULTS
In vivo ovine study
Mechanical testing. The mean mechanical strength of the
defect area containing the scaffold controls was 20% that of
the mean strength of the cancellous bone areas (11.806
7.15 n/mm2 vs. 59.436 27.46 n/mm2, U test: p< 0.01).
The mean mechanical strength of the defect area containing
the scaffold1 SSCs was 11% that of the mean strength of
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the cancellous bone areas (4.616 4.80 n/mm2 vs. 43.056
23.10 n/mm2, U test: p< 0.01) as illustrated in Figure 4.
Comparison of the mean mechanical stress at failure of the
defects containing the scaffold to those containing the scaf-
folds1 SSCs produced a 41 % reduction in stress at posi-
tion 1 (7.886 4.84 n/mm2 vs. 4.636 6.07 n/mm2, U test:
p< 0.01), and a 72 % reduction in stress at position 2
(16.4966.92 n/mm2 vs. 4.586 3.40 n/mm2, U test:
p< 0.01) with the addition of SSCs.
lCT evaluation. Representative images of the lCT recon-
structions of the defects containing scaffold controls and
scaffold1 SSCs are shown in Figure 5. The 3D reconstruc-
tion images [Fig. 5(A,C)] showed that the defects were still
visible in both samples after the 3 month incubation period.
This was to be expected as not all of the scaffold would be
fully resorbed within this timeframe. However, axial slices
demonstrated a sclerotic margin around the samples seeded
with SSCs, indicating that full integration would be limited.
In contrast within the defects ﬁlled with the scaffold alone
there was evidence of normal trabecular bone, indicating
that with extended time, the defect would be completely
ﬁlled.
The mean percentage bone volume content of the
defects ﬁlled with scaffold alone and scaffold1 SSCs was
calculated from the raw lCT data. There was a reduction in
percentage bone volume within the defect of 13.4%
(38.17%6 19.08% vs. 24.81%67.72%) on comparison of
scaffold with the scaffold1 SSCs although this was not sig-
niﬁcant (U test: p5 0.13).
Histological examination
Femoral condyle. Representative images displaying the his-
tological appearance of the femoral condyle defects ﬁlled
with scaffold controls and scaffold1 SSCs are shown in
Figure 6 (A–D). As noted with the lCT ﬁndings, there was
evidence of new bone formation in both the groups, although
the new bone in the scaffold alone defects appeared more
diffuse throughout the defect. The new bone appeared to
integrate more closely with the remaining scaffold material.
Examination under higher magniﬁcation of the areas of
new bone formation it was possible to identify the hydroxy-
apatite particles that were originally from within the poly-
mer scaffold and, evidence of the osteoconductive nature of
these particles [Fig. 6(F)].
Popliteal lymph node. The popliteal lymph nodes serving
the region including the operative site were examined histo-
logically. Representative examples of H1E stains of the
lymph nodes are shown in Figure 7 (A1B). All lymph nodes
presented an essentially normal appearance, although occa-
sional discrete small circular spaces, probably representing
polymer material which had been lost through processing,
were observed; critically, there was no evidence of an overt
inﬂammatory response. This was similar to the histology
seen around the surgical biodegradable sutures, and hence
was likely to be of negligible clinical signiﬁcance.
Parallel in vitro study
WST-1 assay. WST-1 assays were used as a measure of cell
viability on the scaffolds at 2 weeks and 8 weeks time
FIGURE 4. Graph demonstrating the mechanical stress at failure during the indentation test for each of the designated areas (6 SD, n5 6). Posi-
tions 1 and 2 refer to the defect areas containing the scaffolds and positions A and B refer to normal cancellous bone adjacent to the scaffold
(*p< 0.01).
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points (Fig. 8). Signiﬁcant cell growth and viability at both
time points was observed as demonstrated by the large
change in optical density over the 4 h assay period. There
was however a decrease in the ﬁnal optical density achieved
when comparing the 8 week sample to the 2 week sample
(although this was not signiﬁcant (p5 0.16)), possibly
reﬂecting a decrease in viable cell number at this time point
or a reduction in cell metabolic activity, as occurs on
differentiation.
Biochemical analysis. The mean ALP speciﬁc activity at the
2 and 8 week time points was used as a measure of osteo-
blastic differentiation within the SSC population (Fig. 9).
Negligible ALP speciﬁc activity was observed at the 2 week
time point (control value 0.00156 0.0015 nmols PNPP
ALP/hr vs. scaffold1 SSC 0.00660.002 nmols PNPP ALP/
hr), and even though there was a signiﬁcant increase in
alkaline phosphatase speciﬁc activity after 8 weeks (U test:
p< 0.05), the value obtained remained low, indicating mini-
mal osteoblastic differentiation.
Immunostaining. Scaffolds were examined for type-1 colla-
gen, osteocalcin and bone sialoprotein (BSP) immunocyto-
chemistry using confocal microscopy, as potential markers
of osteoblastic differentiation and bone matrix formation
(Fig. 10). There was limited evidence for good bone forma-
tion from the in vitro studies as evidenced by the moderate
positivity for BSP, but only minimal positive staining for
both type-1 collagen and osteocalcin.
DISCUSSION
The use of large animal models is essential when investigat-
ing bone regenerative strategies.13,14 Whilst small animal
studies are warranted when investigating the osteogenic
potential of constructs, as well as allowing an array of sub-
stances to be tested relatively cheaply and quickly, there are
a number of essential factors which are severely comprom-
ized and need careful consideration when interpreting any
subsequent research ﬁndings.18 Small animal models typi-
cally hold limitations in the consideration force and its
impact on skeletal form and bone remodelling.19 Further-
more, the amount of new bone produced, or distance of any
bone defect bridged in a small animal model typically does
not translate proportionately in a larger animal model.
Finally, other issues surrounding distance and time for
ingrowth of blood vessels, and the related survival of any
preseeded cells are not typically addressed by small animal
models.
The ovine femoral condyle defect provides a useful com-
parative model to analyze new bone formation because of
the size of the defect, the surrounding tissue coverage and
blood supply, as well as the nature of the surrounding tra-
becular bone being comparable in nature to human trabecu-
lar bone.2 Given their size, sheep also potentially provide
FIGURE 5. Representative lCT images incorporating the defect site (transected longitudinally) and surrounding host bone of (A) 3D reconstruc-
tion scaffold1SSCs, (B) axial slice through (A) demonstrating sclerotic margin around defect site (arrow), (C) 3D reconstruction scaffold controls
and (D) axial slice through (C) demonstrating new trabecular bone within defect site (white arrow) and small bone defect caused by marker wire
inserted post euthanasia (black arrow). Scale bar5 1 cm.
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models whereby constructs can be exposed to loads and
forces comparable to the human clinical setting. However,
the current model was only minimally loaded (subjected to
the normal physiological load of condylar trabecular bone),
and hence, provided a transitional model to a more complex
loaded model, before a human clinical trial.20 This limitation
does however provide a less complicated, robust model sub-
ject to fewer variables, providing a cost effect method to
screen, and hence further improve and enhance constructs
and experimental protocols prior to evaluation in loaded
(and more expensive) ovine models. This factor has proved
important in this study, whereby the scaffolds examined
FIGURE 6. Histological sections showing defect areas of the sheep condyles stained with toluidine blue and paragon stain. For images A-E scale
bar5500 lm. Images show area packed with polymer (PDLLA HA) alone (A,B) and polymer1SSCs (C,D). New bone formation is shown in pur-
ple (thick white arrows), with fibrous tissue formation in the samples containing SSCs (thick black arrows). The thin white arrows (C) depict the
external margin of the defect, and showed negligible osseointegration had occurred in this region. The thin black arrows represent the remain-
ing polymer. (E) Section of normal sheep condylar cancellous bone. (F) Section taken from within an area of new bone formation (scale
bar5100 lm). A hydroxyapatite particle (thick white arrow) is shown completely encompassed by new bone. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
FIGURE 7. (A,B) Micrographs displaying H1E stains of lymph nodes after the study period. (A) Occasional small circular spaces are visible in
otherwise normal tissue (arrows) (scale bar5 1000 lm), (B) higher magnification of small circular space, showing no increased inflammatory
response around it (scale bar550 lm). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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have provided encouraging results and, has also introduced
important factors for investigation surrounding the potential
of the SSCs and the protocols for their use.
The scaffold, consisting of porous high molecular weight
PDLLA in combination with 10% HA has shown, after a 3
month in vivo incubation period, the potential to stimulate
new bone formation within a critical sized defect of cancel-
lous bone. Both histological and mCT analysis provided good
evidence for new bone formation around and within the con-
structs, although this was incomplete in all cases. Mechanical
indentation tests conﬁrmed these ﬁndings, with structural
integrity within the defects, although the bone was approxi-
mately only one ﬁfth of the strength of that of the neighbor-
ing cancellous bone. This ﬁnding is encouraging and it is
likely that with further time the mechanical strength would
further improve, but further studies would be required to
include these time points and may not be of clinical relevance.
This structural issue is of paramount importance when con-
sidering a fully bioresorbable scaffold for use in a loaded clin-
ical situation. Previous in vitro mechanical tests demonstrated
the composite to have comparable strength to milled allograft
(the current gold standard for large bone defect ﬁlling)
although the comparison in this model is to native cancellous
bone.11,12 A control defect group containing milled allograft,
would allow an accurate comparison to the current gold
standard for bone grafting procedures (not undertaken
because of ﬁscal constraints on experimental group numbers)
but remains for future studies. It would appear over time, in
vivo, the breakdown of the polymer reduced mechanical integ-
rity. The ideal scaffold solution should achieve a balance
whereby the bioresorption and hence loss of strength of the
scaffold is matched by the ingrowth and increase in strength
provided by new bone formation. Shikinami et al. investigated
this process using PLLA/HA composites in a rabbit model,
concluding that composites containing 30% and 40% HA par-
ticles are clinically effective for application in high-strength
bioactive, bioresorbable bone-ﬁxation devices with the
capacity for total bone replacement.21
Consistently throughout the in vivo analyses, this study
has shown that the addition of SSCs was less effective in
the generation of both the volume and quality of new bone
formation in the defect site, as well as the mechanical
strength of the construct/new bone composite. This was
inconsistent with a number of other in vitro and in vivo
studies, where the addition of SSCs was shown to generate
additive effects in terms of enhanced bone formation when
combined with a host of different scaffolds in murine, lap-
ine, and ovine models.15,22–24
The previous papers in this series detail both the in
vitro and small animal in vivo work surrounding the pro-
duction, optimization, and choice of this composite scaffold.
All previous work was performed with the addition of
human SSCs, including evaluation within a murine model
(immunocompromized mice). It has however been shown
that the osteoinductivity of certain substances or culture
conditions is different between human and ovine SSCs.25
The parallel in vitro component of this study examined this
theory, and offers some indication as to why the SSCs may
have been less efﬁcacious in this ovine study. The WST-1
assay showed excellent cell viability on the scaffolds at
2-week and 8-week incubation times indicating biocompati-
bility although, the ALP assay was negative at 2 weeks and
only weakly positive at 8 weeks. These observations indi-
cated a lack of osteoblast differentiation amongst the SSC
population a ﬁnding reinforced with a paucity of type-1 col-
lagen and osteocalcin expression following 8-weeks incuba-
tion. Possible explanations include; either the scaffold was
not osteoinductive to ovine SSCs, or the culture conditions
were not conducive to osteoblast differentiation of the SSC
population. These factors could potentially favor differentia-
tion along less osteogenic populations (ﬁbroblasts), which
could reduce osteoconduction or osteoinduction of sur-
rounding host cells when implanted in vivo. Given the
observation that control scaffolds performed well during the
in vivo study, indicating at least osteoconductivity, it is likely
that it is the initial SSC isolation and seeding protocols
which need to be addressed in order to achieve potential
SSC beneﬁts. Future work will therefore concentrate on this
area, with culture expansion of ovine SSCs in enhanced
osteogenic conditions (e.g., in the presence of BMP-2), and
scaffold seeding at the time of in vivo implantation, such
FIGURE 8. Graphical representation of WST-1 assay showing mean
increase in optical density (minus controls) of the scaffolds seeded
with sheep SSCs at the 2 week (in vivo implantation) and 8 week (in
vivo mid-point) stages (6 SD, n5 6, *p5 0.16).
FIGURE 9. Mean ALP specific activity of the sheep SSC population on
the scaffolds at 2 week and 8 week time points (6 SD, n56,
*p< 0.05).
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that the cells are immediately exposed to the regional
growth factors and stimulatory microenvironments.
Interestingly, a number of studies have shown enhanced
osteoinductivity of biodegradeable scaffolds containing
increasing HA concentrations. Zannettino et al. found that a
15 % concentration of HA was required, whereas Shikinami
et al. found that over 30% was effective in inducing bone for-
mation.21,25 In a previous murine in vivo study performed
with the PDLLA/HA composite scaffold, mCT analysis showed
enhanced bone formation in areas in contact with the HA
particles.12 This therefore suggests additional approaches to
improve the scaffold prior to a second ovine study: (1)
enhancement of HA content and, (2) increasing the availabil-
ity of the HA to the SSCs. The ﬁrst issue could be addressed
by increasing the proportion of HA to PDLLA during the initial
foaming process, whereas the recent development of nano
HA particles suggests a potential solution to enhancement of
availability to skeletal cells. The use of PDLLA with nano HA
in the foaming process offers the potential of a matrix with
HA distributed diffusely throughout the structure and thus a
synthetic bone graft with PDLLA as collagen and the nano HA
as the inorganic components of bone.
CONCLUSIONS
The current studies demonstrated that bone regeneration
occurred in the defects ﬁlled with both the scaffold/SSC
composites and the scaffold controls. However, there was
signiﬁcantly more bone regeneration in the scaffold
controls.
These studies offer further insight toward the successful
translation of a tissue engineered product previously shown
to have encouraging capability in both in vitro and small
animal in vivo studies. The potential of this fully bioresorb-
able composite scaffold to stimulate bone regeneration in a
critical defect has thus been demonstrated in a scaled-up
large animal study. However, there are areas for improve-
ment including: optimization of cell seeding protocols,
including predifferentiation of SSCs or inclusion of osteoin-
ductive stimuli within the scaffolds, the need to address vas-
cularization of the graft or techniques to enhance cell
survival before host vascular ingrowth, and the investigation
of HA concentration and bioavailability. Further research in
these areas is on-going such that future studies should
improve the regenerative capacity of the scaffold, and clini-
cal use of a tissue engineered product is one step closer.
FIGURE 10. Reconstructed 3D immunostain image stacks obtained via confocal microscopy of scaffold1 sheep SSCs after 8 weeks in vitro incu-
bation. Nuclei are shown as red (DAPI) and positivity for the marker is green (alexafluorR 594). (A) control (no primary antibody added), (B)
type-1 collagen, (C) osteocalcin and (D) bone sialoprotein (scale bar5 200 lm). [Color figure can be viewed in the online issue, which is available
at wileyonlinelibrary.com.]
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